INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclon...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Russo |
| Хэвлэсэн: |
IMA PRESS LLC
2016-09-01
|
| Цуврал: | Научно-практическая ревматология |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://rsp.mediar-press.net/rsp/article/view/2255 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|